Remix Therapeutics

Remix Therapeutics Inc. , based in the US, focuses on developing RNA-targeted therapies utilizing its proprietary drug discovery platform to address unmet medical needs in oncology. Founded in 2018 and headquartered in Watertown, US, Remix Therapeutics specializes in RNA-targeted therapy development. The company has engaged in 4 deals and recently raised USD 60 mn in Series B funding on January 3, 2024, led by The Column Group.

CEO Peter Smith is also the founder of the company, indicating continuity in leadership. Remix Therapeutics specializes in innovative RNA-targeted therapies through its proprietary drug discovery platform, focusing on modulating RNA processing with small molecules. Its lead product, REM-422, is a first-in-class small molecule mRNA degrader targeting MYB pre-mRNA, which is linked to several diseases, including adenoid cystic carcinoma. The company aims to create therapeutic options for previously undruggable targets primarily in oncology, enhancing treatment outcomes for cancer patients through clinical trials and partnerships.

Remix Therapeutics generates revenue through strategic collaborations, licensing agreements, and clinical trial partnerships, with potential future income from product sales, particularly from REM-422. Revenue streams include upfront payments, milestone payments tied to clinical trial advancement, and royalties on future sales of marketed products. As it progresses through clinical development, the company aims to establish partnerships that may enhance its financial growth and sustainability. Following the completion of a USD 60 mn Series B funding round in January 2024, Remix Therapeutics plans to advance the clinical development of its lead candidate REM-422 and further its portfolio of RNA-processing targeted therapeutics.

The funding will support these initiatives, aiming to bring new products to market and potentially expand into new geographic regions, targeting broader oncology markets. The timeline for these initiatives is currently aligned with the clinical advancement of their therapies.